- Home
- FINW vs PLX Comparison
FINW vs PLX Comparison
Compare FINW & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINW | PLX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.1M | 230.0M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FINW | PLX |
|---|---|---|
| Price | $15.81 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 8.9K | ★ 1.1M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | N/A | ★ $53,399,000.00 |
| Revenue This Year | $160.48 | $9.67 |
| Revenue Next Year | $35.27 | $23.86 |
| P/E Ratio | $18.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.49 | $1.34 |
| 52 Week High | $22.49 | $3.19 |
Technical Indicators
Market Signals| Indicator | FINW | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 31.15 | 50.71 |
| Support Level | $14.16 | $2.59 |
| Resistance Level | $18.75 | $3.03 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 4.28 | 36.21 |
Price Performance
Historical ComparisonAbout FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.